Sbi Securities Co., Ltd. Viracta Therapeutics, Inc. Transaction History
Sbi Securities Co., Ltd.
- $3.25 Trillion
- Q4 2024
A detailed history of Sbi Securities Co., Ltd. transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Sbi Securities Co., Ltd. holds 180 shares of VIRX stock, worth $14. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180Holding current value
$14% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.64MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$121,6190.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$76,3580.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$55,1760.09% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$40,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$26,5750.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $3M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...